NUCLEUS 24 AUDITORY BRAINSTEM IMPLANT SYSTEM
Cochlear Americas · Decision date Oct 20, 2000
What did the FDA approve?
The FDA approved the Nucleus 24 Auditory Brainstem Implant System for individuals 12 years or older diagnosed with neurofibromatosis type 2. The device is intended to restore useful hearing through electrical stimulation of the cochlear nucleus. Implantation may occur during first or second-side tumor removal, or in patients with previously removed acoustic tumors bilaterally.
The approval statement notes that the surgical procedure for tumor excision and electrode placement eliminates residual hearing, so preoperative audiological criteria are not relevant. Prospective recipients and their families should have appropriate expectations regarding potential benefits and should be motivated to participate in postoperative rehabilitation. The statement reports the device's intended purpose but does not independently establish safety or clinical effectiveness.
FDA approval order statement
APPROVAL FOR THE NUCLEUS 24 AUDITORY BRAINSTEM IMPLANT (ABI) SYSTEM, WHICH IS INTENDED TO RESTORE USEFUL HEARING VIA ELECTRICAL STIMULATION OF THE COCHLEAR NUCLEUS. THE DEVICE IS INDICATED FOR INDIVIDUALS 12 YEARS OF AGE OR OLDER, WHO HAVE BEEN DIAGNOSED WITH NEUROFIBROMATOSIS TYPE 2 (NF2). IMPLANTATION MAY OCCUR DURING FIRST OR SECOND-SIDE TUMOR REMOVAL, OR IN PATIENTS WITH PREVIOUSLY REMOVED ACOUSTIC TUMORS BILATERALLY. BECAUSE THE SURGICAL PROCEDURE FOR TUMOR EXCISION AND ELECTRODE PLACEMENT ELIMINATES RESIDUAL HEARING, PREOPERATIVE AUDIOLOGICAL CRITERIA ARE NOT RELEVANT. PROSPECTIVE IMPLANT RECIPIENTS AND THEIR FAMILIES SHOULD HAVE APPROPRIATE EXPECTATIONS, REGARDING THE POTENTIAL BENEFITS OF AN AUDITORY BRAINSTEM IMPLANT AND SHOULD BE HIGHLY MOTIVATED TO PARTICIPATE IN THE POSTOPEARATIVE REHABILITATION PROCESS.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Ear, Nose, Throat
- Decision date
- Oct 20, 2000
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P000015
- Regulatory pathway
- Premarket approval application
- Applicant
- Cochlear Americas
- Product code
- MHE
- Decision code
- APPR
- Decision date
- Oct 20, 2000
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implant, auditory brainstem.
- Applicant
- Cochlear Americas
- Product code
- MHE
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P000015 received
Application receipt date recorded by FDA.
P000015 · FDA decision
APPR
P000015/S057 · Related supplement
Cochlear Auditory Brainstem Implant System
Timeline entries are records held by MedtechLedger for P000015. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P000015
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Cochlear Auditory Brainstem Implant SystemP000015/S057 | Cochlear Americas | PMA supplement | Sep 28, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Cochlear Americas
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 10350 Park Meadows Dr., Lone Tree, CO, 80124
Sources and methodology
- Original FDA record: P000015
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records